This study focuses on individuals living with Ulcerative Colitis, a long-term condition that causes inflammation and sores in the lining of the large intestine. The purpose of the study is to evaluate the efficacy of vixarelimab compared to a placebo in achieving clinical remission, which is a state where symptoms of the disease are significantly reduced or gone. Participants in the study may also be taking other medications as part of their usual care, such as azathioprine, adalimumab, methotrexate, golimumab, infliximab, mercaptopurine, corticosteroids, or aminosalicylates.

The study consists of an initial phase to see how well the treatment works to control symptoms, followed by an extension period to continue monitoring the effects. During the study, medical professionals will monitor the levels of vixarelimab in the blood and check for anti-drug antibodies, which are substances the body might create in response to a medication. The course of the study involves regular assessments to observe changes in symptoms and the condition of the intestinal lining.